[Clinical evaluation of ACDEMIN in the field of dentistry].
A clinical trial was performed to examine the effect of ACDEMIN, a combination of lysozyme chloride and vitamins (manufactured by Grelan Pharmaceutical Co., Ltd.,; supplied by Takeda Chemical Industries, Ltd.). The subjects were 65 patients with slight to moderate symptoms associated with locally developed diseases including gingivitis, periodontitis, pericoronitis of the wisdom tooth and gingival abscess. Improvement of the condition was evaluated according to symptom on the basis of local findings examined prior to and 7 days after administration. Adverse effects were also evaluated in terms of discomfort. General improvement was determined on the basis of improvement in symptoms and general safety on the basis of a comprehensive assessment of the adverse effects. The usefulness of the drug was determined on the basis of general improvement and general safety as assessed above. The results were as follows: 1) Of the 65 patients who entered the trial, 62 completed the course of administration. 2) The rates of improvement ("slightly improved" or better) according to symptom were 65.6% for gingival inflammation, 40.0% for bleeding, 50.0% for pus discharge, 41.8% for swelling, 61.9% for local pain, 26.7% for mouth odor, 21.7% for color tone and 62.3% for discomfort. 3) The rates of usefulness ("slightly useful" or better) according to disease were 66.7% for gingivitis, 92.0% for periodontitis, 81.8% for pericoronitis of the wisdom tooth and 100.0% for gingival abscess. 4) The usefulness of the drug was graded "very useful" in 4 patients, "fairly useful" in 18, "slightly useful" in 31 and "not useful" in none, with an overall rate of usefulness of 85.5% ("faily useful" or better). 5) No patients presented symptoms indicating an adverse effect.